Atualmente existem medicamentos aprovados para obesidade e diabetes tipo 2 que atuam em receptores relacionados, como agonistas de GLP-1 e agonistas duais de GLP-1/GIP, que j possuem registro em diversas agncias regulatrias
'These medications slow down the transit of food from the stomach to the gut, making you feel full,' Dr Shah says
Together, these actions help explain why GLP-1 has become such an important focus in the treatment of obesity and type 2 diabetes
Lets continue to build the momentum here until we do have more data
Without proper research, patients essentially become test subjects in uncontrolled experiments with their own health
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 201640 for 195 countries and territories